Yahoo Finance's Julia La Roche sits down with executive chairman and former CEO of Starbucks Howard Schultz
|Bid||10.45 x 300|
|Ask||10.98 x 5000|
|Day's Range||10.41 - 10.69|
|52 Week Range||6.27 - 14.63|
|PE Ratio (TTM)||-3.95|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Roche again disappointed this week with two studies on Tecentriq being put on partial hold while Pfizer's Bavencio received approval in Europe. TESARO's Zejula moved a step closer to approval.
Karyopharm's (KPTI) selinexor reduced the risk of progression or death in previously treated patients with advanced dedifferentiated liposarcoma.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Karyopharm Therapeutics, Inc. Here are 5 ETFs with the largest exposure to KPTI-US. Comparing the performance and risk of Karyopharm Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)